Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
IMM
vs
S
S&P/ASX 300
IMM
Over the past 12 months, IMM has underperformed S&P/ASX 300, delivering a return of -90% compared to S&P/ASX 300's 4% drop.
Stocks Performance
IMM vs S&P/ASX 300
Performance Gap
IMM vs S&P/ASX 300
Performance By Year
IMM vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Immutep Ltd
Glance View
Immutep Ltd is a biotechnology company that develops immunotherapy medicines for cancer and autoimmune disease. Its main work is centered on drugs that try to help the immune system work better against tumors or calm it down when the immune system is overactive. The company does not sell consumer products; it sells science, drug candidates, and rights to those programs. Its lead programs are based on the LAG-3 immune checkpoint, a target used to control how immune cells behave. Immutep advances these medicines through clinical development and often works with larger pharmaceutical partners that help fund testing, run trials, or commercialize successful drugs. In practice, the company makes money through partnership payments, research collaboration funding, and, if a drug is approved, potential licensing or royalty income. This makes Immutep different from a drugmaker with approved medicines because its value comes mainly from advancing experimental treatments through the clinic. Its main customers are not patients directly, but pharmaceutical partners, research collaborators, and eventually doctors and hospitals if any product reaches the market. The company sits earlier in the biotech value chain, where scientific results and partnerships matter more than manufacturing or broad sales.